NCT05516992进行中（未招募）3 期
A Phase 3, Multi-center, Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety and Efficacy of SB-01 For Injection for the Treatment of Lumbar Degenerative Disc Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
- 试验地点
- 28
- 主要终点
- Change from Baseline in function on the Oswestry Disability Index (ODI) at 6 months.
研究概览
简要总结
The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease. The primary effectiveness hypothesis is superiority of the investigational product relative to control in terms of the percentage of subjects improving in pain-related disability.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Double-blind, placebo-controlled study.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older
- •Back pain greater than 'worst leg pain' as measured by the NRS
- •Diagnosed with one or two contiguous level(s) lumbar (L1-S1) disc degeneration of Pfirrmann Grade 3 and/or 4 determined by MRI analyzed by the independent radiologic central lab
- •Have chronic low back pain and related disability for at least 6 months with at least 3 months of prior conservative treatment
- •Baseline ODI score ≥ 40/100
- •Baseline NRS ≥ 4 points (Back)
- •Willing and able to provide Informed Consent for study participation
- •Willing and able to comply with this protocol and be available for the entire duration of the study, including ability to access the internet
- •Must practice effective contraception during the first 3 months of follow-up (female of childbearing potential and male subjects):
- •Abstinence or,
- •Surgical Sterilization or,
- •Oral Contraceptives or,
- •Barrier Methods (Condoms, IUD's).
- •Patient must verify that:
- •In the case of females, the patient is post-menopausal or is surgically sterile or,
- •In the case of males, the patient is surgically sterile or,
- •The patient (male or female) confirms that they are at a point in their life where they are beyond consideration of having children.
排除标准
- •To qualify for enrollment in this study, patients must meet none of the exclusion criteria as follows.
- •Prior epidural, sacroiliac joint, or facet injections at any lumbosacral level within the past 4 weeks (e.g., transforaminal, interlaminar, caudal)
- •Prior interventional procedures of other types at any lumbosacral level at any time (e.g., intradiscal injection, basivertebral nerve ablation, biacuplasty; radiofrequency (RF) ablation, spinal cord stimulator, others)
- •Prior spine surgery at any lumbosacral level at any time (e.g., discectomy, decompression, instrumentation, fusion, fracture treatment, others)
- •Prior fracture at any lumbar level
- •Significant neurologic symptoms:
- •Grade 3/5 or lower strength in any lumbar myotome
- •Sensory deficit in a clearly radicular or sensory dermatome
- •MRI evidence of disc height loss > 2/3 of adjacent disc at any level to be injected, determined by the independent radiologic central lab
- •MRI evidence of other disc degeneration: Pfirrmann Grade 3-5 at any level not to be injected, determined by the independent radiologic central lab
- •MRI evidence of disc herniation with neural compression at any level, determined by the independent radiologic central lab
- •MRI evidence of significant stenosis of the central canal at any level, determined by the independent radiologic central lab
- •MRI evidence of foraminal stenosis with neural compression at any level, determined by the independent radiologic central lab
- •MRI evidence of moderate-to-severe facet arthrosis with edema at any level, determined by the independent radiologic central lab
- •Spondylolisthesis (antero or retrolisthesis) > 25% at any level, determined by the independent radiologic central lab
- •Lumbar coronal deformity, determined by the independent radiologic central lab:
- •a. L1-S1 regional deformity > 25 degrees
- •Spondylolysis at any level
- •Lumbar inflammatory spondylitis
- •Recent history (previous six months) of chemical or alcohol dependence
- •Chronic narcotic use for more than defined as a daily dose of greater than 40 Morphine Equivalent Units (MEUs)
- •Depression or Somatization defined through the Distress and Risk Assessment Method (DRAM) scoring with Zung score > 33 or Zung > 17 and the Modified Somatic Perception Questionnaire (MSPQ) score > 12
- •Extreme obesity, defined by NIH Clinical Guidelines Body Mass Index (BMI > 40)
- •A QT duration corrected for heart rate by Fridericia's formula (QTcF) > 470 millisecond (msec)
- •Active systemic infection
- •Infection at the site of procedure pre-operatively
- •Cauda equina syndrome or neurogenic bowel/bladder dysfunction
- •Any terminal, systemic, or autoimmune disease including fibromyalgia, which may, in the opinion of the Principal Investigator compromise a subject's ability to comply with study procedures, and/or confound data
- •Metabolic bone disease (e.g., osteoporosis/osteopenia, gout, osteomalacia, Paget's disease)
- •Any disease, condition or surgery which might impair healing, such as:
- •Active malignancy
- •History of metastatic malignancy
- •Currently experiencing an episode of major mental illness (psychosis, major affective disorder, or schizophrenia), or manifesting physical symptoms without a diagnosable medical condition to account for the symptoms, which may indicate symptoms of psychological rather than physical origin
- •Any planned surgical procedure within the subject participation period (screening through the 12 Month Visit)
- •Any clinically relevant laboratory result on the screening visit Chem-12, hematology, or coagulation panels
- •Pregnancy at the time of screening, randomization, or planning to become pregnant during the first 3 months of follow-up
- •Currently a prisoner
- •Participation in any other investigational drug, biologic, or medical device study within the last 6 months prior to study procedure
- •Receiving Work Compensation benefits or engaged in personal spinal injury medical/legal litigation
- •Patient cannot be currently using the prohibited medications listed in the protocol
研究组 & 干预措施
SB-01 For Injection
Experimental
Subjects receive a SB-01 For Injection intradiscal injection per treated disc.
干预措施: SB-01 For Injection (Drug)
Sham Needle
Placebo Comparator
Subjects receive a sham needle placement for each treated disc.
干预措施: Sham Needle (Drug)
结局指标
主要结局
Change from Baseline in function on the Oswestry Disability Index (ODI) at 6 months.
时间窗: Baseline/Screening and 6 Month
The ODI is a validated, 10-item self-reported instrument assessment of pain-related disability. Possible scores range from 0 (no disability) - 50 (severe disability). Further calculations are applied to reach a percentage score.
次要结局
- Change from Baseline in pain on the Numerical Rating Scale (NRS) at 6 months. This outcome will only be tested if the primary endpoint is met.(Baseline/Screening and 6 Month)
研究者
研究点 (28)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar LinesGlabellar LinesNCT02493946Ipsen600
已完成
3 期
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)LymphomaNCT01889069Hoffmann-La Roche159
已完成
3 期
To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)InfertilityNCT00702845Organon and Co397
已完成
3 期
A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT01987479Hoffmann-La Roche150
已完成
2 期
Different Volumes of Durolane in Knee OAKnee OsteoarthritisNCT01265459Galderma R&D68